BioLineRx Ltd. (BLRX): Price and Financial Metrics

BioLineRx Ltd. (BLRX): $1.58

0.13 (+8.97%)

POWR Rating

Component Grades













Add BLRX to Watchlist
Sign Up

Industry: Biotech



in industry

BLRX Stock Price Chart Interactive Chart >

Price chart for BLRX

BLRX Price/Volume Stats

Current price $1.58 52-week high $3.62
Prev. close $1.45 52-week low $1.01
Day low $1.41 Volume 337,400
Day high $1.63 Avg. volume 232,216
50-day MA $1.44 Dividend yield N/A
200-day MA $2.13 Market Cap 75.33M

BioLineRx Ltd. (BLRX) Company Bio

BioLineRx Ltd., a clinical stage biopharmaceutical development company, engages in identifying, in-licensing, and developing therapeutic candidates that address unmet medical needs. The company was founded in 2003 and is based in Modi’in, Israel.

BLRX Latest News Stream

Event/Time News Detail
Loading, please wait...

BLRX Latest Social Stream

Loading social stream, please wait...

View Full BLRX Social Stream

Latest BLRX News From Around the Web

Below are the latest news stories about BioLineRx Ltd that investors may wish to consider to help them evaluate BLRX as an investment opportunity.

BLRX: Initiating on BioLineRx: Mobilizing the Troops with Motixafortide

By John Vandermosten, CFA NASDAQ:BLRX READ THE FULL BLRX RESEARCH REPORT We are initiating on BioLineRx Ltd. (NASDAQ:BLRX) with our valuation based on the company’s progress advancing Motixafortide for the mobilization of hematopoietic stem cells (HSCs) for autologous transplantation in subjects with multiple myeloma (MM). Pivotal trials for this indication have been completed, a pre-new drug

Yahoo | January 31, 2022

BioLineRx Announces Completion of Enrollment of Phase 1/2a Study of Innovative Intratumoral Cancer Vaccine, AGI-134, in Unresectable Metastatic Solid Tumors

BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical Company focused on oncology, today announced that the Company has completed enrollment of the Phase 1/2a study of its innovative intratumoral cancer vaccine candidate, AGI-134, designed to evaluate the safety and biological activity of AGI-134 in patients with unresectable metastatic solid tumors. Results of AGI-134's safety and proof of mechanism are anticipated in the first half of 2022.

Yahoo | January 24, 2022

Biolinerx (BLRX) Receives a Buy from H.C. Wainwright

H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Biolinerx (BLRX – Research Report) today and set a price target of $19.00. The company's shares closed last Tuesday at $2.01, close to its 52-week low of $1.93. According to, Pantginis ' ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -13.7% and a 24.5% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Lineage Cell Therapeutics, and Actinium Pharmaceuticals. The word on The Street in general, suggests a Hold analyst consensus rating for Biolinerx.

Brian Anderson on TipRanks | January 18, 2022

BioLineRx Announces Successful Completion of Pre-NDA Meeting with FDA for Motixafortide for Stem Cell Mobilization in Multiple Myeloma Patients

BioLineRx Ltd. (NASDAQ-CM: BLRX) (TASE: BLRX) a late clinical-stage biopharmaceutical company focused on oncology, today announced that the Company has completed a successful pre-New Drug Application (NDA) meeting with the US Food and Drug Administration (FDA) regarding Motixafortide as a novel stem-cell mobilization agent for autologous bone marrow transplantation in multiple myeloma patients.

Yahoo | January 18, 2022

BioLineRx Ltd. (NASDAQ:BLRX) Short Interest Down 36.7% in November

BioLineRx Ltd. (NASDAQ:BLRX) was the recipient of a large decrease in short interest in the month of November. As of November 30th, there was short interest totalling 116,700 shares, a decrease of 36.7% from the November 15th total of 184,500 shares. Based on an average daily trading volume, of 368,500 shares, the days-to-cover ratio is []

Dakota Financial News | December 18, 2021

Read More 'BLRX' Stories Here

BLRX Price Returns

1-mo 29.51%
3-mo 3.95%
6-mo -39.92%
1-year -44.76%
3-year -71.49%
5-year -87.46%
YTD -22.55%
2021 -19.05%
2020 12.00%
2019 -65.91%
2018 -59.63%
2017 18.48%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.5613 seconds.